Bone regeneration: Stem cell therapies and clinical studies in orthopaedics and traumatology

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 6, 2011, Pages 1266-1286

  Gómez Barrena, Enrique ^a   Rosset, Philippe ^b   Müller, Ingo ^c   Giordano, Rosaria ^d   Bunu, Carmen ^e   Layrolle, Pierre ^f   Konttinen, Yrjö T ^g,h,i   Luyten, Frank P ^j  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^e VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^f UNIVERSITÉ DE NANTES   (France)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h ORTON ORTHOPAEDIC HOSPITAL   (Finland)

ⁱ COXA Hospital for Joint Replacement ^*  (Finland)

^j UNIVERSITY OF LEUVEN   (Belgium)

more..

Author keywords

Bone regeneration; Clinical studies; Ethics; Regenerative medicine; Stem cell therapy

Indexed keywords

ADULT; ARTICLE; BONE; BONE REGENERATION; CLINICAL TRIAL (TOPIC); CONGENITAL MALFORMATION; ETHICS; HUMAN; MEDICAL RESEARCH; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; METHODOLOGY; ORTHOPEDICS; PATHOLOGY; PRESCHOOL CHILD; REGENERATIVE MEDICINE; TISSUE ENGINEERING; TRAUMATOLOGY;

ADULT; BIOMEDICAL RESEARCH; BONE AND BONES; BONE REGENERATION; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; ORTHOPEDICS; REGENERATIVE MEDICINE; RESEARCH DESIGN; TISSUE ENGINEERING; TRAUMATOLOGY;

EID: 79957650575     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01265.x     Document Type: Article

References (129)

1. Burchardt H. Biology of bone transplantation. Orthop Clin North Am. 1987; 18: 187-96.
2. De Groot K. Ceramics of calcium phosphates: preparation and properties. Bioceramics of calcium phosphate Boca Raton FL: CRC Press; 1983.
3. Daculsi G. Biphasic calcium phosphate concept applied to artificial bone, implant coating and injectable bone substitute. Biomaterials. 1998; 19: 1473-8.
4. Laurencin C, Khan Y, El-Amin SF. Bone graft substitutes. Expert Rev Med Devices. 2006; 3: 49-57.
5. Fellah BH, Gauthier O, Weiss P, et al Osteogenicity of biphasic calcium phosphate ceramics and bone autograft in a goat model. Biomaterials. 2008; 29: 1177-88.
6. Langer R, Vacanti JP. Tissue engineering. Science. 1993; 260: 920-6.
7. Petite H, Viateau V, Bensaid W, et al Tissue-engineered bone regeneration. Nat Biotechnol. 2000; 18: 959-63.
8. Derubeis AR, Cancedda R. Bone marrow stromal cells (BMSCs) in bone engineering: limitations and recent advances. Ann Biomed Eng. 2004; 32: 160-5.
9. Khan Y, Yaszemski MJ, Mikos AG, et al Tissue engineering of bone: material and matrix considerations. J Bone Joint Surg Am. 2008; 90: 36-42.
10. Giannoudis P, Einhorn T. Bone morphogenetic proteins - applications in orthopaedic and trauma surgery. London: Elsevier; 2010.
11. Garrison KR, Shemilt I, Donell S, et al Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst Rev. 2010; 6: CD006950.
12. Schallmoser K, Rohde E, Reinisch A, et al Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum. Tissue Eng Part C Methods. 2008; 14: 185-96.
13. Di Nicola M, Carlo-Stella C, Magni M, et al Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002; 99: 3838-43.
14. Dominici M, Le Blanc K, Mueller I, et al Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8: 315-7.
15. Crisan M, Chen CW, Corselli M, et al Perivascular multipotent progenitor cells in human organs. Ann N Y Acad Sci. 2009; 1176: 118-23.
16. Bieback K, Kern S, Kluter H, et al Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells. 2004; 22: 625-34.
17. Xin Y, Wang YM, Zhang H, et al Aging adversely impacts biological properties of human bone marrow-derived mesenchymal stem cells: implications for tissue engineering heart valve construction. Artif Organs. 2010; 34: 215-22.
18. Shi YY, Nacamuli RP, Salim A, et al The osteogenic potential of adipose-derived mesenchymal cells is maintained with aging. Plast Reconstr Surg. 2005; 116: 1686-96.
19. van Harmelen V, Skurk T, Rohrig K, et al Effect of BMI and age on adipose tissue cellularity and differentiation capacity in women. Int J Obes Relat Metab Disord. 2003; 27: 889-95.
20. Jurgens WJ, Oedayrajsingh-Varma MJ, Helder MN, et al Effect of tissue-harvesting site on yield of stem cells derived from adipose tissue: implications for cell-based therapies. Cell Tissue Res. 2008; 332: 415-26.
21. Marx RE, Carlson ER, Eichstaedt RM, et al Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998; 85: 638-46.
22. Chevallier N, Anagnostou F, Zilber S, et al Osteoblastic differentiation of human mesenchymal stem cells with platelet lysate. Biomaterials. 2010; 31: 270-8.
23. Anselme K, Broux O, Noel B, et al In vitro control of human bone marrow stromal cells for bone tissue engineering. Tissue Eng. 2002; 8: 941-53.
24. Materna T, Rolf HJ, Napp J, et al In vitro characterization of three-dimensional scaffolds seeded with human bone marrow stromal cells for tissue engineered growth of bone: mission impossible? A methodological approach. Clin Oral Implants Res. 2008; 19: 379-86.
25. Giannoni P, Muraglia A, Giordano C, et al Osteogenic differentiation of human mesenchymal stromal cells on surface-modified titanium alloys for orthopedic and dental implants. Int J Artif Organs. 2009; 32: 811-20.
26. Mastrogiacomo M, Scaglione S, Martinetti R, et al Role of scaffold internal structure on in vivo bone formation in macroporous calcium phosphate bioceramics. Biomaterials. 2006; 27: 3230-7.
27. Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991; 9: 641-50.
28. Bruder SP, Jaiswal N, Haynesworth SE. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem. 1997; 64: 278-94.
29. Sacchetti B, Funari A, Michienzi S, et al Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell. 2007; 131: 324-36.
30. de Girolamo L, Sartori MF, Albisetti W, et al Osteogenic differentiation of human adipose-derived stem cells: comparison of two different inductive media. J Tissue Eng Regen Med. 2007; 1: 154-7.
31. Lee JH, Rhie JW, Oh DY, et al Osteogenic differentiation of human adipose tissue-derived stromal cells (hASCs) in a porous three-dimensional scaffold. Biochem Biophys Res Commun. 2008; 370: 456-60.
32. De Bari C, Dell'Accio F, Vanlauwe J, et al Mesenchymal multipotency of adult human periosteal cells demonstrated by single-cell lineage analysis. Arthritis Rheum. 2006; 54: 1209-21.
33. Eyckmans J, Luyten FP. Species specificity of ectopic bone formation using periosteum-derived mesenchymal progenitor cells. Tissue Eng. 2006; 12: 2203-13.
34. Vinatier C, Guicheux J, Daculsi G, et al Cartilage and bone tissue engineering using hydrogels. Biomed Mater Eng. 2006; 16: S107-13.
35. Lenas P, Moos M, Luyten FP. Developmental engineering: a new paradigm for the design and manufacturing of cell-based products. Part I: from three-dimensional cell growth to biomimetics of in vivo development. Tissue Eng B Rev. 2009; 15: 381-94.
36. Lenas P, Moos M, Luyten FP. Developmental engineering: a new paradigm for the design and manufacturing of cell-based products. Part II: from genes to networks: tissue engineering from the viewpoint of systems biology and network science. Tissue Eng B Rev. 2009; 15: 395-422.
37. Scotti C, Tonnarelli B, Papadimitropoulos A, et al Recapitulation of endochondral bone formation using human adult mesenchymal stem cells as a paradigm for developmental engineering. Proc Natl Acad Sci USA. 2010; 107: 7251-6.
38. Zhang S, Greenfield MA, Mata A, et al A self-assembly pathway to aligned monodomain gels. Nat Mater. 2010; 9: 594-601.
39. Ladet S, David L, Domard A. Multi-membrane hydrogels. Nature. 2008; 452: 76-9.
40. Fellah BH, Weiss P, Gauthier O, et al Bone repair using a new injectable self-crosslinkable bone substitute. J Orthop Res. 2006; 24: 628-35.
41. Masquelet AC, Begue T. The concept of induced membrane for reconstruction of long bone defects. Orthop Clin North Am. 2010; 41: 27-37.
42. Connolly JF, Guse R, Tiedeman J, et al Autologous marrow injection for delayed unions of the tibia: a preliminary report. J Orthop Trauma. 1989; 3: 276-82.
43. Connolly JF, Guse R, Tiedeman J, et al Autologous marrow injection as a substitute for operative grafting of tibial nonunions. Clin Orthop Relat Res. 1991; 259-70.
44. Garg NK, Gaur S, Sharma S. Percutaneous autogenous bone marrow grafting in 20 cases of ununited fracture. Acta Orthop Scand. 1993; 64: 671-2.
45. Hernigou P, Poignard A, Beaujean F, et al Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. J Bone Joint Surg Am. 2005; 87: 1430-7.
46. Neen D, Noyes D, Shaw M, et al Healos and bone marrow aspirate used for lumbar spine fusion: a case controlled study comparing healos with autograft. Spine. 2006; 31: E636-40.
47. Ateschrang A, Ochs BG, Ludemann M, et al Fibula and tibia fusion with cancellous allograft vitalised with autologous bone marrow: first results for infected tibial non-union. Arch Orthop Trauma Surg. 2009; 129: 97-104.
48. Dallari D, Savarino L, Stagni C, et al Enhanced tibial osteotomy healing with use of bone grafts supplemented with platelet gel or platelet gel and bone marrow stromal cells. J Bone Joint Surg Am. 2007; 89: 2413-20.
49. Gan Y, Dai K, Zhang P, et al The clinical use of enriched bone marrow stem cells combined with porous beta-tricalcium phosphate in posterior spinal fusion. Biomaterials. 2008; 29: 3973-82.
50. Kitoh H, Kitakoji T, Tsuchiya H, et al Distraction osteogenesis of the lower extremity in patients with achondroplasia/hypochondroplasia treated with transplantation of culture-expanded bone marrow cells and platelet-rich plasma. J Pediatr Orthop. 2007; 27: 629-34.
51. Kitoh H, Kawasumi M, Kaneko H, et al Differential effects of culture-expanded bone marrow cells on the regeneration of bone between the femoral and the tibial lengthenings. J Pediatr Orthop. 2009; 29: 643-9.
52. Kim SJ, Shin YW, Yang KH, et al A multi-center, randomized, clinical study to compare the effect and safety of autologous cultured osteoblast(Ossron) injection to treat fractures. BMC Musculoskelet Disord. 2009; 10: 20-9.
53. Bajada S, Harrison PE, Ashton BA, et al Successful treatment of refractory tibial nonunion using calcium sulphate and bone marrow stromal cell implantation. J Bone Joint Surg Br. 2007; 89: 1382-6.
54. Wright JG, Yandow S, Donaldson S, et al A randomized clinical trial comparing intralesional bone marrow and steroid injections for simple bone cysts. J Bone Joint Surg Am. 2008; 90: 722-30.
55. Zamzam MM, Abak AA, Bakarman KA, et al Efficacy of aspiration and autogenous bone marrow injection in the treatment of simple bone cysts. Int Orthop. 2009; 33: 1353-8.
56. Tiedeman JJ, Garvin KL, Kile TA, et al The role of a composite, demineralized bone matrix and bone marrow in the treatment of osseous defects. Orthopedics. 1995; 18: 1153-8.
57. Park IH, Micic ID, Jeon IH. A study of 23 unicameral bone cysts of the calcaneus: open chip allogeneic bone graft versus percutaneous injection of bone powder with autogenous bone marrow. Foot Ankle Int. 2008; 29: 164-70.
58. Ochs BG, Schmid U, Rieth J, et al Acetabular bone reconstruction in revision arthroplasty: a comparison of freeze-dried, irradiated and chemically-treated allograft vitalised with autologous marrow versus frozen non-irradiated allograft. J Bone Joint Surg Br. 2008; 90: 1164-71.
59. Jäger M, Jelinek EM, Wess KM, et al Bone marrow concentrate: a novel strategy for bone defect treatment. Curr Stem Cell Res Ther. 2009; 4: 34-43.
60. Quarto R, Mastrogiacomo M, Cancedda R, et al Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med. 2001; 344: 385-6.
61. Marcacci M, Kon E, Moukhachev V, et al Stem cells associated with macroporous bioceramics for long bone repair: 6- to 7-year outcome of a pilot clinical study. Tissue Eng. 2007; 13: 947-55.
62. Vacanti CA, Bonassar LJ, Vacanti MP, et al Replacement of an avulsed phalanx with tissue-engineered bone. N Engl J Med. 2001; 344: 1511-4.
63. Morishita T, Honoki K, Ohgushi H, et al Tissue engineering approach to the treatment of bone tumors: three cases of cultured bone grafts derived from patients' mesenchymal stem cells. Artif Organs. 2006; 30: 115-8.
64. Meijer GJ, de Bruijn JD, Koole R, et al Cell based bone tissue engineering in jaw defects. Biomaterials. 2008; 29: 3053-61.
65. Warnke PH, Springer IN, Wiltfang J, et al Growth and transplantation of a custom vascularised bone graft in a man. Lancet. 2004; 364: 766-70.
66. Warnke PH, Wiltfang J, Springer I, et al Man as living bioreactor: fate of an exogenously prepared customized tissue-engineered mandible. Biomaterials. 2006; 27: 3163-7.
67. Hernigou P, Beaujean F, Lambotte JC. Decrease in the mesenchymal stem-cell pool in the proximal femur in corticosteroid-induced osteonecrosis. JBone Joint SurgBr. 1999; 81: 349-55.
68. Hernigou P, Beaujean F. Treatment of osteonecrosis with autologous bone marrow grafting. ClinOrthopRelat Res. 2002; 14-23.
69. Hernigou P, Poignard A, Zilber S, et al Cell therapy of hip osteonecrosis with autologous bone marrow grafting. Indian J Orthop. 2009; 43: 40-5.
70. Gangji V, Hauzeur JP, Matos C, et al Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. A pilot study. J Bone Joint Surg Am. 2004; 86-A: 1153-60.
71. Yamasaki T, Yasunaga Y, Ishikawa M, et al Bone-marrow-derived mononuclear cells with a porous hydroxyapatite scaffold for the treatment of osteonecrosis of the femoral head: a preliminary study. J Bone Joint Surg Br. 2010; 92: 337-41.
72. Cohen MM Jr. The new bone biology: pathologic, molecular, and clinical correlates. Am J Med Genet A. 2006; 140: 2646-706.
73. Stark Z, Savarirayan R. Osteopetrosis. Orphanet J Rare Dis. 2009; 4: 5-17.
74. Steward CG. Hematopoietic stem cell transplantation for osteopetrosis. Pediatr Clin North Am. 2010; 57: 171-80.
75. Driessen GJ, Gerritsen EJ, Fischer A, et al Long-term outcome of haematopoietic stem cell transplantation in autosomal recessive osteopetrosis: an EBMT report. Bone Marrow Transplant. 2003; 32: 657-63.
76. Shapiro JR, Sponsellor PD. Osteogenesis imperfecta: questions and answers. Curr Opin Pediatr. 2009; 21: 709-16.
77. Horwitz EM, Prockop DJ, Gordon PL, et al Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood. 2001; 97: 1227-31.
78. Le Blanc K, Gotherstrom C, Ringden O, et al Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation. 2005; 79: 1607-14.
79. Horwitz EM, Prockop DJ, Fitzpatrick LA, et al Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999; 5: 309-13.
80. Horwitz EM, Gordon PL, Koo WK, et al Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA. 2002; 99: 8932-7.
81. Dominici M, Marino R, Rasini V, et al Donor cell-derived osteopoiesis originates from a self-renewing stem cell with a limited regenerative contribution after transplantation. Blood. 2008; 111: 4386-91.
82. Aldenhoven M, Sakkers RJ, Boelens J, et al Musculoskeletal manifestations of lysosomal storage disorders. AnnRheumDis. 2009; 68: 1659-65.
83. Sauer M, Meissner B, Fuchs D, et al Allogeneic blood SCT for children with Hurler's syndrome: results from the German multicenter approach MPS-HCT 2005. Bone Marrow Transplant. 2009; 43: 375-81.
84. Willasch A, Hoelle W, Kreyenberg H, et al Outcome of allogeneic stem cell transplantation in children with non-malignant diseases. Haematologica. 2006; 91: 788-94.
85. Kwan MD, Slater BJ, Wan DC, et al Cell-based therapies for skeletal regenerative medicine. Hum Mol Genet. 2008; 17: R93-8.
86. Jethva R, Otsuru S, Dominici M, et al Cell therapy for disorders of bone. Cytotherapy. 2009; 11: 3-17.
87. Burger B, Beier R, Zimmermann M, et al Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL) - experiences from trial ALL-BFM 95. Pediatr Blood Cancer. 2005; 44: 220-5.
88. Adekile AD, Gupta R, Yacoub F, et al Avascular necrosis of the hip in children with sickle cell disease and high Hb F: magnetic resonance imaging findings and influence of alpha-thalassemia trait. Acta Haematol. 2001; 105: 27-31.
89. Kobayakawa M, Rydholm U, Wingstrand H, et al Femoral head necrosis in juvenile chronic arthritis. Acta Orthop Scand. 1989; 60: 164-9.
90. Castro FP Jr, Barrack RL. Core decompression and conservative treatment for avascular necrosis of the femoral head: a meta-analysis. Am J Orthop. 2000; 29: 187-94.
91. Beltran J, Knight CT, Zuelzer WA, et al Core decompression for avascular necrosis of the femoral head: correlation between long-term results and preoperative MR staging. Radiology. 1990; 175: 533-6.
92. Low K, Mont MA, Hungerford DS. Steroid-associated osteonecrosis of the knee: a comprehensive review. Instr Course Lect. 2001; 50: 489-93.
93. Simank HG, Brocai DR, Strauch K, et al Core decompression in osteonecrosis of the femoral head: risk-factor-dependent outcome evaluation using survivorship analysis. Int Orthop. 1999; 23: 154-9.
94. Yan ZQ, Chen YS, Li WJ, et al Treatment of osteonecrosis of the femoral head by percutaneous decompression and autologous bone marrow mononuclear cell infusion. Chin J Traumatol. 2006; 9: 3-7.
95. Datta N, Holtorf HL, Sikavitsas VI, et al Effect of bone extracellular matrix synthesized in vitro on the osteoblastic differentiation of marrow stromal cells. Biomaterials. 2005; 26: 971-7.
96. Kotobuki N, Hirose M, Machida H, et al Viability and osteogenic potential of cryopreserved human bone marrow-derived mesenchymal cells. Tissue Eng. 2005; 11: 663-73.
97. Kraus KH, Kirker-Head C. Mesenchymal stem cells and bone regeneration. Vet Surg. 2006; 35: 232-42.
98. Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells. 2007; 25: 2896-902.
99. Liechty KW, MacKenzie TC, Shaaban AF, et al Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med. 2000; 6: 1282-6.
100. Meyerrose TE, De Ugarte DA, Hofling AA, et al In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models. Stem Cells. 2007; 25: 220-7.
101. Wang Z, Goh J, Das DS, et al Efficacy of bone marrow-derived stem cells in strengthening osteoporotic bone in a rabbit model. Tissue Eng. 2006; 12: 1753-61.
102. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. JCell Biochem. 2006; 98: 1076-84.
103. Noiseux N, Gnecchi M, Lopez-Ilasaca M, et al Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther. 2006; 14: 840-50.
104. Müller I, Vaegler M, Holzwarth C, et al Secretion of angiogenic proteins by human multipotent mesenchymal stromal cells and their clinical potential in the treatment of avascular osteonecrosis. Leukemia. 2008; 22: 2054-61.
105. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126: 663-76.
106. Cave E, Nichols C. Clinical audit and reform of the UK research ethics review system. Theor Med Bioeth. 2007; 28: 181-203.
107. Jones NL. A code of ethics for the life sciences. Sci Eng Ethics. 2007; 13: 25-43.
108. Oduncu FS. Stem cell research in Germany: ethics of healing versus human dignity. Med Health Care Philos. 2003; 6: 5-16.
109. Doerflinger R. Destructive stem-cell research on human embryos. Origins. 1999; 28: 769, 71-73.
110. Lo B, Parham L. Ethical issues in stem cell research. Endocr Rev. 2009; 30: 204-13.
111. Isasi RM, Knoppers BM. Beyond the permissibility of embryonic and stem cell research: substantive requirements and procedural safeguards. Hum Reprod. 2006; 21: 2474-81.
112. Mertes H, Pennings G, Van Steirteghem A. An ethical analysis of alternative methods to obtain pluripotent stem cells without destroying embryos. Hum Reprod. 2006; 21: 2749-55.
113. Holm S. The ethical case against stem cell research. Camb Q Healthc Ethics. 2003; 12: 372-83.
114. Cregan K. Ethical and social issues of embryonic stem cell technology. Intern Med J. 2005; 35: 126-7.
115. McCullough LB, Chervenak FA. Ethics in obstetrics and gynecology. Oxford, UK: Oxford University Press; 1994.
116. Human Stem Cell Research and Regenerative Medicine. A European Perspective on Scientific, Ethical and Legal Issues. Available at (Accessed 2 Feb 2011).
117. Code of Nuremberg. Available at (Accessed 2 Feb 2011).
118. Slavicek G, Forsdahl G. Ethics and regulatory aspects in medical research. Int J Stomat Occ Med. 2009; 2: 45-9.
119. Declaration of Helsinki. Available at (Accessed 2 Feb 2011).
120. Convention of the Council of Europe for the Protection of Human Rights and Dignity of the Human Being regarding the Application of Biology and Medicine. Convention on Human Rights and Biomedicine signed in Oviedo on 4th April 1997, and the additional protocols. Available at (Accessed 2 Feb 2011).
121. Directive 2004/23/EC. Available at (Accessed 2 Feb 2011).
122. Opinion of EGE No. 15/2000. Ethical aspects of human stem cell research and use. Available at (Accessed 2 Feb 2011).
123. Berry RM. Informed consent law, ethics, and practice: from infancy to reflective adolescence. HEC Forum. 2005; 17: 64-81.
124. Schroter S, Plowman R, Hutchings A, et al Reporting ethics committee approval and patient consent by study design in five general medical journals. J Med Ethics. 2006; 32: 718-23.
125. Opinion of EGE No. 11/1998. Ethical aspects of human tissue banking. Available at (Accessed 2 Feb 2011).
126. Opinion of EGE No. 13/1999. Ethical issues on healthcare in the information society. Available at (Accessed 2 Feb 2011).
127. Hansson SO. Uncertainty and the ethics of clinical trials. Theor Med Bioeth. 2006; 27: 149-67.
128. Dresser R. Private-sector research ethics: marketing or good conflicts management? The 2005 John J. Conley Lecture on Medical Ethics. Theor Med Bioeth. 2006; 27: 115-39.
129. De Angelis C, Drazen JM, Frizelle FA, et al Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Circulation. 2005; 111: 1337-8.